Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition

Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies

Denise M. Adams, Cameron C. Trenor, Adrienne M. Hammill et al. · PEDIATRICS · 2016 · 830 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacotherapy +13

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto et al. · The Lancet Oncology · 2017 · 491 citations · Full text

Medicine, Oncology, Pharmacology +10

ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor

Dong Li, Michael March, Álvaro Gutiérrez-Uzquiza et al. · Nature Medicine · 2019 · 219 citations

Medicine, Cell Biology, Molecular Medicine +11

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

Shripad V. Bhagwat, Prafulla C. Gokhale, Andrew P. Crew et al. · Molecular Cancer Therapeutics · 2011 · 201 citations

Medicine, Oncology, Pharmacology +13

Kaposiform Lymphangiomatosis: A Distinct Aggressive Lymphatic Anomaly

Stacy E. Croteau, Harry P. Kozakewich, Antonio R. Pérez‐Atayde et al. · The Journal of Pediatrics · 2013 · 169 citations · Full text

Medicine, Immunology, Pathology +9